Estland - estisk - Ravimiamet

b. braun melsungen ag - midasolaam - süste-/infusioonilahus - 5mg 1ml 10ml 5tk; 5mg 1ml 10ml 4tk; 5mg 1ml 10ml 10tk; 5mg 1ml 10ml 20tk; 5mg 1ml 3ml 10tk

Estland - estisk - Ravimiamet

shire pharmaceuticals contracts limited - mesalasiin - gastroresistentne toimeainet prolongeeritult vabastav tablett - 1200mg 120tk; 1200mg 60tk

Estland - estisk - Ravimiamet

bayer ag - gadobutrool - süstelahus - 1mmol 1ml 15ml 10tk; 1mmol 1ml 30ml 1tk; 1mmol 1ml 7.5ml 1tk; 1mmol 1ml 7.5ml 10tk

Estland - estisk - Ravimiamet

johnson & johnson uab - norgestimaat+etünüülöstradiool - tablett - 0,25mg+0,035mg 21tk; 0,25mg+0,035mg 63tk

Estland - estisk - Ravimiamet

bayer ag - gadobutrool - süstelahus süstlis - 1mmol 1ml 7.5ml 5tk; 1mmol 1ml 5ml 5tk; 1mmol 1ml 7.5ml 1tk; 1mmol 1ml 10ml 1tk; 1mmol 1ml 15ml 5tk

Estland - estisk - Ravimiamet

sandoz pharmaceuticals d.d. - vankomütsiin - infusioonilahuse pulber - 1000mg 10tk; 1000mg 5tk

Estland - estisk - Ravimiamet

sandoz pharmaceuticals d.d. - tenofoviirdisoproksiil - õhukese polümeerikattega tablett - 245mg 60tk; 245mg 30tk

Den Europæiske Union - estisk - EMA (European Medicines Agency)

bluebird bio (netherlands) b.v. - elivaldogene autotemcel - adrenoleukodystrophy - muud närvisüsteemi ravimid - treatment of early cerebral adrenoleukodystrophy in patients less than 18 years of age, with an abcd1 genetic mutation, and for whom a human leukocyte antigen (hla) matched sibling haematopoietic stem cell donor is not available.

Den Europæiske Union - estisk - EMA (European Medicines Agency)

janssen-cilag international n.v.    - amivantamab - kartsinoom, mitteväikerakk-kopsu - antineoplastilised ained - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.

Den Europæiske Union - estisk - EMA (European Medicines Agency)

ascendis pharma endocrinology division a/s - lonapegsomatropin - growth and development - hüpofüüsi ja hüpotaalamuse hormoonid ja analoogid - growth failure in children and adolescents aged from 3 years up to 18 years due to insufficient endogenous growth hormone secretion (growth hormone deficiency [ghd]),.